Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity

Ultragenyx (RARE) outlook: 2026 revenue guidance, cost controls, and key FDA/PDUFA catalysts (DTX401, UX111, GTX-102).

Read on WOBR AI →